Catalyst Pharmaceuticals stock falls 4.01% and underperforms competitors in mixed session
Updated
Updated · MarketWatch · Apr 29
Catalyst Pharmaceuticals stock falls 4.01% and underperforms competitors in mixed session
4 articles · Updated · MarketWatch · Apr 29
Catalyst Pharmaceuticals shares closed at $28.26 on Wednesday, snapping a two-day winning streak and trading 13.21% below its 52-week high of $32.56 set on April 27.
The drop occurred amid a mixed market, with the NASDAQ Composite Index rising 0.04% and the Dow Jones Industrial Average falling 0.57%. Trading volume reached 1.6 million, above the 50-day average.
Catalyst Pharmaceuticals underperformed major peers like Johnson & Johnson, Pfizer, and Abbott Laboratories, all of which also saw declines but to a lesser extent during the session.
Why did Catalyst stock plunge 4% despite record earnings and a 'Strong Buy' rating?
Trading at a 50% discount to its value, is Catalyst the biggest bargain in biotech?
With $1 billion for acquisitions, what rare-disease company will Catalyst buy next?
What surprise could Catalyst reveal in its upcoming May 11th earnings call?
Is a rival drug's off-label use a secret threat to Catalyst's main cash cow?
Can the new drug AGAMREE become a bigger blockbuster than its flagship FIRDAPSE?